Novel antiviral therapies with overwhelmingly positive sustained virologic response rates have dominated headlines in hepatitis C virus for the past few years, but many experts said eradication efforts may never completely succeed until the clinical community deals with mother-to-baby transmission of the disease.
20 January 2015 | EATG
The ChemSex and hepatitis C: a discussion guide for HCPs has been developed by 56 Dean Street's David Stuart, who has a wealth of experience in providing drug addiction services to HIV/HCV co-infected MSM. The guide, endorsed by The Hepatitis C Trust, is based on over 500 conversations with MSM, aims to inform healthcare professionals and services providers across the UK around ChemSex (the use of recreational drugs for sex) and HIV/HCV co-infection to empower them to use the terminology that will most resonate with these at-risk groups, and to ensure they are being diagnosed and treated effectively.
29 December 2014 | 56 Dean Street, via Medical News Today
Increasing evidence suggests that hepatitis C transmits sexually among HIV-negative men who have sex with men, and not just among HIV-positive MSM.
26 December 2014 | AIDSMeds
A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.
19 December 2014 | Eurekalert Inf Dis
Injecting drug users will be offered a breakthrough treatment for hepatitis C as part of a Melbourne study to assess whether treating them can reduce transmission of the virus in the community.
17 December 2014 | Sydney Morning Herald
Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with hepatitis, a top government health official said on Friday. Some also get HIV.
09 December 2014 | HepatitisCNewDrugs
A new vaccine developed by researchers at the University of Oxford has generated a strong immune response against the Hepatitis C virus in human volunteers. The vaccine is the first Hepatitis C inoculation to reach this stage of clinical trials, and the results have been promising. The 15 healthy human volunteers who took part in the phase 1 safety trial all responded positively.The study found that after the second, booster inoculation, all 15 volunteers had large, broad and sustained T cells responses.
26 November 2014 | Cherwell
The aim of this document is to reinforce the need for urgent leadership from the Department of Health, PHE and NHS England and concerted action from Local Authorities, Health and Wellbeing Boards, Clinical Commissioning Groups (CCGs) and service providers to improve hepatitis C testing and treatment services in London for people with a history of using drugs – the group most affected by chronic hepatitis C – in order to find and treat significantly more people affected by the disease.
17 November 2014 | London Joint Working Group on Substance Use and Hepatitis C
Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."
05 November 2014 | Public Health England press release
Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.
29 October 2014 | HIVandhepatitis.com